Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination.

Peter M IzmirlyMimi Y KimMarie SamanovicRuth Fernandez-RuizSharon OhanaKristina K DeonaraineAlexis J EngelMala MassonXianhong XieAmber R CorneliusRamin S HeratiRebecca H HabermanJose U ScherAllison GuttmannRebecca B BlankBenjamin PlotzMayce Haj-AliBrittany BanburySara StreamGhadeer HasanGary HoPaula RackoffAshira D BlazerChung-E TsengH Michael BelmontAmit SaxenaMark J MulliganRobert M ClancyJill P Buyon

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

In a multi-ethnic/racial study of SLE patients 29% had a low response to the COVID-19 vaccine which was associated with being on immunosuppression. Reassuringly, disease flares were rare. While minimal protective levels remain unknown, these data suggest protocol development is needed to assess efficacy of booster vaccination.

Keyphrases

sars cov
end stage renal disease
immune response
systemic lupus erythematosus
coronavirus disease
randomized controlled trial
prognostic factors
machine learning
patient reported outcomes
patient reported